Perseverance Capital

Perseverance Capital Management is an asset management firm based in Los Angeles, California, specializing in investing in the healthcare sector. Founded in 2013, the firm takes a long-term approach to investing and actively collaborates with portfolio company management teams to build market-leading companies. By forming deep partnerships with scientists, clinicians, entrepreneurs, and management teams, Perseverance aims to not only achieve long-term capital appreciation for investors but also to make a meaningful impact on patients' lives.

Ben Shyong

Partner

5 past transactions

Galactic Holdings

Seed Round in 2023
Galactic Holdings offers a comprehensive suite of digital finance products. Its flagship product, TruBit, facilitates convenient fiat on/off ramps and payment solutions tailored for the LATAM region. Additionally, Galactic Holdings provides TruBit Pro, an advanced trading exchange, and Moneta (MMXN), a stablecoin pegged to the Mexican peso.

MindRhythm

Seed Round in 2021
MindRhythm is a medical device company dedicated to improving the diagnosis, triage, and management of stroke and concussion patients through innovative biometrics. The company has developed proprietary monitoring devices and a communication platform that offer real-time visibility into critical situations, both prehospital and in the operating room. This technology empowers clinicians to intervene promptly and accurately, significantly reducing the risk of brain damage in patients experiencing neurological emergencies. By focusing on enhancing patient outcomes in acute care settings, MindRhythm aims to transform the approach to neurological injury prevention and management.

CG Oncology

Series D in 2020
CG Oncology is a clinical-stage biopharmaceutical company dedicated to developing novel immunotherapies for cancer patients. It specializes in oncolytic immunotherapy, focusing on bladder cancer treatments.

CG Oncology

Series C in 2019
CG Oncology is a clinical-stage biopharmaceutical company dedicated to developing novel immunotherapies for cancer patients. It specializes in oncolytic immunotherapy, focusing on bladder cancer treatments.

NxThera

Series C in 2014
NxThera, founded in 2008 and headquartered in Maple Grove, Minnesota, specializes in the development of medical technologies for treating endourological conditions. The company's core technology involves convective water vapor energy, designed to deliver minimally invasive, thermal therapy for conditions such as benign prostatic hyperplasia (BPH), which affects over 32 million men in the U.S. As of April 30, 2018, NxThera operates as a subsidiary of Boston Scientific Corporation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.